Advertisement

Topics

Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation

11:11 EDT 23 Sep 2016 | Biotech-Finances

Friday, September 23rd 2016 at 12:30pm UTC Transaction expected to close in the Third-Quarter 2016 NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended has expired with respect to Pfizer’s pending acquisition of Medivation, Inc. (NASDAQ: MDVN). Pfizer now expects to …

Cet article Pfizer Announces Expiration of HSR Waiting Period For Proposed
Acquisition of Medivation
est apparu en premier sur EEI-BIOTECHFINANCES.

Original Article: Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation

NEXT ARTICLE

More From BioPortfolio on "Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation"

Quick Search
Advertisement
 

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...